Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Mayo Clinic
Fox Chase Cancer Center
Ohio State University Comprehensive Cancer Center
Canadian Cancer Trials Group
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine
Columbia University
University of California, San Francisco
Yale University
Celgene
Celgene
Northwestern University
National Cancer Institute (NCI)
NYU Langone Health
M.D. Anderson Cancer Center
Virginia Commonwealth University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)